• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcellx Inc. (Amendment)

    2/14/24 4:48:55 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    SC 13G/A 1 d783014dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Arcellx, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    03940C 100

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03940C 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,544,809

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,544,809

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,544,809

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA

     


    CUSIP No. 03940C 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,544,809

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,544,809

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,544,809

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     


    CUSIP No. 03940C 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,544,809

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,544,809

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,544,809

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO

     


    Item 1(a).

    Name of Issuer:

    Arcellx, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    25 West Watkins Mill Road, Suite A, Gaithersburg, MD 20878

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    03940C 100

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on an aggregate of 51,928,729 shares of Common Stock, consisting of (i) 48,686,187 outstanding shares of Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023, and (ii) 3,242,542 shares of Common Stock issued on December 28, 2023, in connection with a certain purchase agreement, as reported in the Issuer’s Current Report on Form 10-K filed on December 28, 2023.


    The Master Fund directly holds 4,544,809 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:  Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:  Managing Member

     

    Get the next $ACLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    5/31/2024$70.00Overweight
    Piper Sandler
    3/7/2024$81.00Overweight
    Morgan Stanley
    1/4/2024$65.00 → $71.00Buy
    Needham
    12/19/2023$66.00Sector Outperform
    Scotiabank
    10/30/2023Outperform
    TD Cowen
    10/17/2023$52.00Buy
    UBS
    More analyst ratings

    $ACLX
    Financials

    Live finance-specific insights

    See more
    • Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

      -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

      12/9/22 8:15:00 AM ET
      $ACLX
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcellx Inc.

      SC 13G - Arcellx, Inc. (0001786205) (Subject)

      11/22/24 4:12:28 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:35:36 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:31:50 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    SEC Filings

    See more
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/28/25 4:34:31 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

      SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

      5/15/25 4:30:15 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/14/25 10:08:40 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

      -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

      3/20/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

      REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

      6/21/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Appoints Michelle Gilson as Chief Financial Officer

      FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

      5/23/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Redburn Atlantic initiated coverage on Arcellx with a new price target

      Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00

      10/8/24 7:12:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Arcellx

      Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight

      9/3/24 7:38:42 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Arcellx with a new price target

      Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00

      5/31/24 7:34:12 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

      Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy) A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 3

      5/21/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

      -- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies f

      5/14/25 9:30:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

      -- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise -- -- Ended the quarter with $565M in cash, which is expected to fund operations into 2028 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. "Delivering therapies that can positively impact patients' lives is our mission," said Rami Elg

      5/8/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Behbahani Ali

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:33:05 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Galligan Andrew H

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:24:21 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Patel Kavita

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:20:49 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care